The effect of nobiletin on performance of rats in forced swimming and elevated plus maze tests in intranigral lipopolysaccharide rat model of Parkinson's disease

Document Type: Research Paper

Authors

1 Department of Physiology, School of Medicine, Shahed University, Tehran, Iran

2 Neurophysiology Research Center, Shahed University, Tehran, Iran

10.22070/jbcp.2020.4355.1115

Abstract

Background and Objective: Anti-inflammatory property of nobiletin (NOB) is proven and neuroinflammation is involved in triggering and progression of neurodegenerative disorder such as Parkinson's disease (PD). PD is a neurodegenerative disorder characterized by motor and non-motor features including psychiatric symptoms such as depression and anxiety. The purpose of this study to investigate whether oral nobiletin administration at a dose of 10 mg/kg has the ability to alleviate non-motor behavioural changes including depression and anxiety-like behaviors in LPS-induced model of PD in rat.
Materials and Methods: For this purpose, 32 male Wistar rats (195-245 g) were divided into four groups (n=8) as follows: Sham-operated group, nobiletin-treated sham-operated group (sham+NOB), lesion group (LPS) and nobiletin-treated lesion group (LPS+NOB). LPS (5 μg/kg) rat was unilaterally injected into the SN of rat brains through standard stereotaxis, according to the atlas of Paxinos and Watson (to generate a neuroinflammatory model of PD), with or without NOB (10 mg/kg administrated daily for 1 week after surgery, via gavage). Behavioral assessment was carried out one week after surgery by assessment of performance in forced swimming and elevated plus maze tests.
Results: NOB-treated LPS group showed significant decrease in immobility time and insignificant increase in the percentage of open arm spending time as compared with LPS group which demonstrate the anti-depressant like effect of NOB in inflammatory model of PD in rats.
Conclusion: Taken together, this study demonstrated that nobiletin as an anxiolytic and anti-depressive agent in the LPS-induced rat model of Parkinson’s disease.

Keywords


  1. Braak H, Del Tredici K, Rüb U, De Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging 2003;24(2):197-211.
  2. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Movement Disorders 2006;21(7):916-23.
  3. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 1999;22:123-44.
  4. Olanow CW. The pathogenesis of cell death in Parkinson's disease--2007. Movement Disorders 2007;22 Suppl 17:S335-42.
  5. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Movement Disorders 2014;29(13):1583-90.
  6. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson's disease. Journal of Clinical Epidemiology 2002;55(1):25-31.
  7. Fields JA. Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. Archives of Clinical Beuropsychology 2017;32(7):786-801.
  8. Schrag A, Taddei RN. Depression and Anxiety in Parkinson's Disease. International Review of Neurobiology 2017;133:623-55.
  9. Sharma N, Nehru B. Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation. Neurochemistry International 2015;87:92-105.
  10. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2011;1(1):a009316.
  11. Castano A, Herrera A, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry 1998;70(4):1584-92.
  12. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002 ; 110 (1) : 49 -58.
  13. Liu B, Jiang J-W, Wilson BC, Du L, Yang S-N, Wang J-Y, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. Journal of Pharmacology and Experimental Therapeutics 2000;295(1):125-32.
  14. Liu B, Du L, Hong J-S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. Journal of Pharmacology and Experimental Therapeutics 2000;293(2):607-17.
  15. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS, et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Movement Disorders 2002;17(1):116-24.
  16. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. Role of nitric oxide in inflammation‐mediated neurodegeneration. Annals of the New York Academy of Sciences 2002;962(1):318-31.
  17. Chao C, Hu S, Molitor T, Shaskan E, Peterson P. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. The Journal of Immunology 1992;149(8):2736-41.
  18. Dawson V, Brahmbhatt H, Mong J, Dawson TM. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 1994;33(11):1425-30.
  19. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. Journal of Neurochemistry 2002;81(6):1285-97.
  20. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain research. Developmental Brain Research 2002;133(1):27-35.
  21. Jeohn GH, Kim WG, Hong JS. Time dependency of the action of nitric oxide in lipopolysaccharide-interferon-gamma-induced neuronal cell death in murine primary neuron-glia co-cultures. Brain Research 2000;880(1-2):173-7.
  22. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999;28(2):114-27.
  23. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Experimental Neurology 2001;169(2):219-30.
  24. Ciesielska A, Joniec I, Przybylkowski A, Gromadzka G, Kurkowska-Jastrzebska I, Czlonkowska A, et al. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiologiae Experimentalis 2003;63(2):117-26.
  25. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. The European Journal of Neuroscience 2003;18(10):2731-42.
  26. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences of the United States of America 1992;89(16):7384-8.
  27. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. The Journal of Biological Chemistry 1992;267(36):25934-8.
  28. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. The Journal of Biological Chemistry 1996;271(52):33157-60.
  29. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Jr., et al. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. The Journal of Biological Chemistry 2001;276(32):30188-98.
  30. Wang T, Qin L, Liu B, Liu Y, Wilson B, Eling TE, et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. Journal of Neurochemistry 2004;88(4):939-47.
  31. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. The Journal of Biological Chemistry 2004;279(2):1415-21.
  32. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Advances in Experimental Medicine and Biology 1999;468:123-33.
  33. Lin N, Sato T, Takayama Y, Mimaki Y, Sashida Y, Yano M, et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochemical Pharmacology 2003;65(12):2065-71.
  34. Murakami A, Shigemori T, Ohigashi H. Zingiberaceous and citrus constituents, 1'-acetoxychavicol acetate, zerumbone, auraptene, and nobiletin, suppress lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 murine macrophages through different modes of action. The Journal of Nutrition 2005;135(12 Suppl):2987s-92s.
  35. Li J, Zhou Y, Liu BB, Liu Q, Geng D, Weng LJ, et al. Nobiletin Ameliorates the Deficits in Hippocampal BDNF, TrkB, and Synapsin I Induced by Chronic Unpredictable Mild Stress. Evidence-based Complementary and Alternative Medicine 2013;2013:359682.
  36. Yabuki Y, Ohizumi Y, Yokosuka A, Mimaki Y, Fukunaga K. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice. Neuroscience 2014;259:126-41.
  37. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nature reviews. Drug Discovery 2006;5(10):845-54.
  38. Yi LT, Xu HL, Feng J, Zhan X, Zhou LP, Cui CC. Involvement of monoaminergic systems in the antidepressant-like effect of nobiletin. Physiology & Behavior 2011;102(1):1-6.
  39. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. The New England Journal of Medicine 2000;342(20):1484-91.
  40. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Journal of Neurology 2005;252 Suppl 4:Iv37-iv42.
  41. Melo LM, Chien HF, Barbosa ER. Identification of wearing-off manifestations (reduction of levodopa effect) in Parkinson's disease using specific questionnaire and comparison of the results with routine ambulatory evaluations. Arquivos de Neuro-psiquiatria 2010;68(4):506-10.
  42. Baluchnejadmojarad T, Roghani M. Effect of naringenin on intracerebroventricular streptozotocin-induced cognitive deficits in rat: a behavioral analysis. Pharmacology 2006;78(4):193-7.
  43. Paxinos G, Watson C. The rat brain in stereotaxic coordinates: hard cover edition: Elsevier; 2006.
  44. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie 1977;229(2):327-36.
  45. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266(5604):730-2.
  46. Castagne V, Moser P, Roux S, Porsolt RD. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Current Protocols in Neuroscience 2011;Chapter 8:Unit 8.10A.
  47. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behavioural Pharmacology 1997;8(6-7):523-32.
  48. Asakawa T, Fang H, Sugiyama K, Nozaki T, Hong Z, Yang Y, et al. Animal behavioral assessments in current research of Parkinson's disease. Neuroscience and Biobehavioral Reviews 2016;65:63-94.
  49. Hritcu L, Cioanca O, Hancianu M. Effects of lavender oil inhalation on improving scopolamine-induced spatial memory impairment in laboratory rats. Phytomedicine 2012;19(6):529-34.
  50. Lee M, Ryu YH, Cho WG, Kang YW, Lee SJ, Jeon TJ, et al. Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. Synapse (New York, N.Y.) 2015;69(9):453-60.
  51. Grundmann O, Nakajima J, Seo S, Butterweck V. Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test. Journal of Ethnopharmacology 2007;110(3):406-11.
  52. Foyet HS, Hritcu L, Ciobica A, Stefan M, Kamtchouing P, Cojocaru D. Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson's disease. Journal of Ethnopharmacology 2011;133(2):773-9.
  53. Mao QQ, Ip SP, Tsai SH, Che CT. Antidepressant-like effect of peony glycosides in mice. Journal of Ethnopharmacology 2008;119(2):272-5.
  54. Tolardo R, Zetterman L, Bitencourtt DR, Mora TC, de Oliveira FL, Biavatti MW, et al. Evaluation of behavioral and pharmacological effects of Hedyosmum brasiliense and isolated sesquiterpene lactones in rodents. Journal of Ethnopharmacology 2010;128(1):63-70.